{"denoms":[{"counts":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"140"}],"units":"Participants"}],"groups":[{"description":"Patients receive (10 mg/mL x 2.5 mL) 25 mg doxepin hydrochloride (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.","id":"BG000","title":"Arm I (Doxepin-Placebo)"},{"description":"Patients receive 2.5 mL placebo (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.","id":"BG001","title":"Arm II (Placebo-Doxepin)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"39.0","upperLimit":"93.0","value":"62"},{"groupId":"BG001","lowerLimit":"37.0","upperLimit":"86.0","value":"60"},{"groupId":"BG002","lowerLimit":"37.0","upperLimit":"93.0","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"112"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"140"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}